June 2016 Vol 7, No 5

It is my great pleasure to welcome you to this issue of JONS, the official publication of the Academy of Oncology Nurse & Patient Navigators (AONN+).
JONS speaks with Lillie D. Shockney, RN, BS, MAS, about the role of the navigator in personalizing care for oncology patients and the future for the profession.
AONN+ recognizes that for oncology navigators to excel in this competitive environment they must be empowered with the education and skill sets that are necessary to fulfill the responsibilities of their position. Certification is the answer to this need.
The authors present reports on the important role of nurse navigations in care coordination and operations management to assist navigators in preparing for the coming certification test.
In preparation for the upcoming certification test, information is provided on the essential function of nurse navigations in care coordination to assist navigators.
The following are a selection of key clinical trials that are currently recruiting patients for inclusion in investigations of new therapies or new combinations of available therapies for patients with kidney cancer, including renal cell carcinoma. Each trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their eligible patients to one of these clinical trials.
Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
CancerLinQ is a powerful database containing vast amounts of usable, searchable, real-world cancer information, created by oncologists, for oncologists, to improve the quality of patient care.
The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy.
Page 1 of 2
Results 1 - 10 of 16

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State